MedTrace Logo

Nebulised Heparin to Reduce COVID-19 Induced Acute Lung Injury

NCT04511923 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2024-07-24

No results posted yet for this study

Summary

The investigators present a randomised open label phase Ib/IIa trial of nebulised unfractionated heparin to evaluate the effect of nebulised unfractionated heparin on the procoagulant response in ICU patients with SARS-CoV-2 requiring advanced respiratory support. As this is one of the first studies of nebulised heparin in COVID 19 lung disease the investigators will assess safety as a co-primary outcome.

Conditions

  • Covid19
  • ARDS, Human
  • Lung Injury, Acute
  • Ventilation Perfusion Mismatch

Interventions

DRUG

Nebulised heparin

Nebulised unfractionated heparin 25000 units administered 6 hourly for 10 days

Sponsors & Collaborators

  • University College Hospital Galway

    lead OTHER

Principal Investigators

  • John Laffey · Professor of Anaesthesia and Intensive Care Medicine, National University of Ireland, Galway, Ireland

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-23
Primary Completion
2021-12-31
Completion
2022-02-28

Countries

  • Ireland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04511923 on ClinicalTrials.gov